Wolstenholme J L, Smith S J, Whynes D K
University of Nottingham.
Int J Technol Assess Health Care. 1998 Spring;14(2):277-89. doi: 10.1017/s0266462300012253.
Total treatment costs by stage at diagnosis are estimated for a sample of breast cancer patients. At 4 years, stage 4 cancers emerge as being more expensive to treat than those at earlier stages, although this difference fails to achieve significance when expected lifetime costs are considered. The inclusion of treatment cost estimates in a screening model indicates that screening may increase expected treatment costs by a marginal amount, although the model also suggests that the cost-effectiveness ratio of breast cancer screening might be better than had originally been thought.
对一组乳腺癌患者样本估算了确诊时各阶段的总治疗成本。在4年时，4期癌症的治疗成本比早期阶段的癌症更高，不过在考虑预期终生成本时，这种差异并不显著。在筛查模型中纳入治疗成本估算表明，筛查可能会使预期治疗成本略有增加，尽管该模型也表明乳腺癌筛查的成本效益比可能比原先认为的要好。
